{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:39:51Z","timestamp":1792237191201,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>RO7049389 (linvencorvir) is a developmental oral treatment for chronic hepatitis B virus infection. The aim of this work was to conduct mass balance (MB) and absolute bioavailability (BA) analyses in healthy volunteers, alongside in vitro evaluations of the metabolism of RO7049389 and a major circulating active metabolite M5 in human hepatocytes, and physiologically based pharmacokinetic (PBPK) modelling to refine the underlying drug disposition paradigm.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants in the clinical study (MB: Caucasian, male, <jats:italic>n<\/jats:italic>\u2009=\u20096; BA: Caucasian and Asian, male and female, <jats:italic>n<\/jats:italic>\u2009=\u200916, 8 in each ethnic groups) received oral [<jats:sup>14<\/jats:sup>C] or unlabelled RO7049389 (600\/1000\u2009mg) followed by 100\u2009\u03bcg intravenous [<jats:sup>13<\/jats:sup>C]RO7049389. Metabolic pathways with fractions metabolized\u2014obtained from the in vitro incubation results of 10\u00a0\u03bcM [<jats:sup>14<\/jats:sup>C]RO7049389 and 1\u00a0\u03bcM\u2009M5 with (long\u2010term cocultured) human hepatocytes in the absence and presence of the cytochrome P450 3A4 (CYP3A4) inhibitor itraconazole\u2014were used to complement the PBPK models, alongside the clinical MB and BA data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The model performance in predicting the pharmacokinetic profiles of RO7049389 and M5 aligned with clinical observations in Caucasians and was also successfully applied to Asians. Accordingly, the drug disposition pathways for RO7049389 were postulated with newly characterized estimates of the fractions: biliary excretion by P\u2010glycoprotein (~41%), direct glucuronidation via uridine 5\u2032\u2010diphosphoglucuronosyltransferase 1A3 (~11%), hexose conjugation (~6%), oxidation by CYP3A4 (~28%) and other oxidation reactions (~9%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results support the ongoing clinical development program for RO7049389 and highlight the broader value of PBPK and MB analyses in drug development.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15809","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T08:20:47Z","timestamp":1685694047000},"page":"3079-3091","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the drug disposition of RO7049389 with in vitro data and human mass balance supported by physiologically based pharmacokinetic modelling"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2233-3063","authenticated-orcid":false,"given":"Yuchen","family":"Zhang","sequence":"first","affiliation":[{"name":"Roche Pharma Research &amp; Early Development China Innovation Center of Roche  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Umehara","sequence":"additional","affiliation":[{"name":"Roche Pharma Research &amp; Early Development Roche Innovation Center  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-2480","authenticated-orcid":false,"given":"Andrea A.","family":"Romeo","sequence":"additional","affiliation":[{"name":"Roche Pharma Research &amp; Early Development Roche Innovation Center  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nand","family":"Singh","sequence":"additional","affiliation":[{"name":"Quotient Sciences  Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Cantrill","sequence":"additional","affiliation":[{"name":"Roche Pharma Research &amp; Early Development Roche Innovation Center  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Savage","sequence":"additional","affiliation":[{"name":"York Bioanalytical Solutions  Sandwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Chen","sequence":"additional","affiliation":[{"name":"Roche (China) Holding  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Roche Pharma Research &amp; Early Development China Innovation Center of Roche  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil John","family":"Parrot","sequence":"additional","affiliation":[{"name":"Roche Pharma Research &amp; Early Development Roche Innovation Center  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Paehler","sequence":"additional","affiliation":[{"name":"Roche Pharma Research &amp; Early Development Roche Innovation Center  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_10_3_1","unstructured":"World Health Organization.Hepatitis B.2022. Accessed November 29 2022.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01323-20"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2184"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(21)00176\u2010X"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13134"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000778340.70278.c8"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000133"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2092"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000765"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1361"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.053397fullarticlecorrection"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13882"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14748"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.65040"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004268128"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.04.074"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.146647"},{"key":"e_1_2_10_21_1","unstructured":"University of Washington.Drug Interaction Database.2022. Accessed November 29 2022.https:\/\/didb.druginteractionsolutions.org\/"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.206"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.090852"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2691"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T06:08:42Z","timestamp":1698041322000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/bcp.15809"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15809","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]}}}